IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/11/26	€0.0750	0.00%	0
30/10/26	€0.0750	+15.38%	11,771
29/10/26	€0.0650	-12.16%	30,641
28/10/26	€0.0740	+25.85%	123,894
27/10/26	€0.0588	-42.35%	31,141

Real-time Euronext Paris

More quotes

Real-time Euronext Paris 00:55:00 03/11/2026 HKT			5-day change	1st Jan Change
0.0750 ^EUR	0.00%		-26.47%	-43.61%

10-30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
10-12	ABL Texcell Diagnostics to Acquire French Biotech Company IntegraGen	MT

Market Cap	881K 986K 808K 735K 1.38M 93.37M 1.41M 9.65M 3.89M 49.28M 3.7M 3.62M 156M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.5M -2.04M -1.86M -3.49M -236M -3.56M -24.42M -9.85M -125M -9.37M -9.17M -394M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

10-30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
10-12	ABL Texcell Diagnostics to Acquire French Biotech Company IntegraGen	MT
10-12	ABL Diagnostics Société anonyme completed the acquisition of Business operations and assets of IntegraGen SA for ?0.1 million.	CI
10-06	Verdict on October 9 on IntegraGen's future
09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
06-16	IntegraGen Enters Receivership Proceedings
05-29	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/10/25	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/07/25	IntegraGen SA Reports Sales Results for the First Half of 2025	CI

IntegraGen Stock

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
30/04/25	IntegraGen: 2024 Annual Results	BU
16/01/25	IntegraGen : Inside Information / Information on annual revenues	PU
16/01/25	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

10-30	IntegraGen : Résultats estimés du 1er semestre 2026
10-27	IntegraGen poursuit son activité auprès de ses clients et partenaires dans l’attente de la décision de la Cour d’appel de Paris
10-12	IntegraGen annonce la cession de ses activités et actifs à ABL Diagnostics et son placement en liquidation judiciaire
10-12	Bourse : LVMH en piste ce soir, Stellantis sort une 2CV, NVidia et Amazon s'offrent des garanties
10-12	ABL Texcell Diagnostics reprend les actifs et les activités d'IntegraGen

1 week	-26.47%
1 month	+7.14%
3 months	-59.68%
6 months	-55.62%
Current year	-43.61%

1 week	0.06	0.09
1 month	0.01	0.12
Current year	0.01	0.36
1 year	0.01	0.36
3 years	0.01	1.05
5 years	0.01	2.04
10 years	0.01	3.96

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	09/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	01/01/2023
Berengere Genin COO	Chief Operating Officer	-	01/01/2024

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	22/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	01/01/2021
François Blondel BRD	Director/Board Member	63	31/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	0.00%	-26.47%	-50.33%	-92.33%	554K
WUXI APPTEC CO., LTD.	-2.37%	-5.03%	+39.49%	+62.39%	62.23B
ARGENX SE	-0.18%	+0.03%	+10.31%	+68.17%	54.92B
LONZA GROUP AG	-0.25%	+1.76%	+19.99%	+96.60%	55.26B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+19.39%	+35.69%	42.59B
BEONE MEDICINES AG	-2.45%	-2.59%	+16.36%	+98.45%	41.08B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+219.80%	+789.69%	40.33B
GENMAB A/S	+0.08%	+23.39%	+98.34%	+83.07%	33.12B
CELLTRION, INC.	+0.21%	+1.05%	+14.81%	+46.96%	32.61B
INSMED INCORPORATED	-2.90%	+17.12%	-42.35%	+337.07%	23.98B
Average	-1.27%	+1.06%	+34.58%	+152.58%	38.61B
Weighted average by Cap.	-1.38%	+2.74%	+44.59%	+162.50%

	2019	2020
Net sales	8.28M 9.27M 7.6M 6.91M 12.96M 878M 13.22M 90.75M 36.58M 463M 34.81M 34.06M 1.46B	9M 10.08M 8.26M 7.51M 14.09M 954M 14.37M 98.64M 39.76M 504M 37.83M 37.03M 1.59B
Net income	-285K -319K -261K -238K -446K -30.2M -455K -3.12M -1.26M -15.94M -1.2M -1.17M -50.35M	-375K -420K -344K -313K -587K -39.76M -599K -4.11M -1.66M -20.99M -1.58M -1.54M -66.29M
Net Debt	-2.52M -2.82M -2.31M -2.1M -3.94M -267M -4.02M -27.61M -11.13M -141M -10.59M -10.36M -445M	-3.11M -3.48M -2.85M -2.6M -4.87M -330M -4.96M -34.08M -13.74M -174M -13.07M -12.79M -550M